This company has been marked as potentially delisted and may not be actively trading. Nightstar Therapeutics (NITE) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock NITE vs. SRRK, SWTX, IMVT, ALVO, IBRX, TWST, RXRX, VCEL, DNLI, and TARSShould you be buying Nightstar Therapeutics stock or one of its competitors? The main competitors of Nightstar Therapeutics include Scholar Rock (SRRK), SpringWorks Therapeutics (SWTX), Immunovant (IMVT), Alvotech (ALVO), ImmunityBio (IBRX), Twist Bioscience (TWST), Recursion Pharmaceuticals (RXRX), Vericel (VCEL), Denali Therapeutics (DNLI), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "medical" sector. Nightstar Therapeutics vs. Scholar Rock SpringWorks Therapeutics Immunovant Alvotech ImmunityBio Twist Bioscience Recursion Pharmaceuticals Vericel Denali Therapeutics Tarsus Pharmaceuticals Nightstar Therapeutics (NASDAQ:NITE) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk. Is NITE or SRRK more profitable? Nightstar Therapeutics' return on equity of -30.89% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Nightstar TherapeuticsN/A -30.89% -27.65% Scholar Rock N/A -145.60%-91.83% Does the MarketBeat Community favor NITE or SRRK? Nightstar Therapeutics received 56 more outperform votes than Scholar Rock when rated by MarketBeat users. Likewise, 69.88% of users gave Nightstar Therapeutics an outperform vote while only 66.27% of users gave Scholar Rock an outperform vote. CompanyUnderperformOutperformNightstar TherapeuticsOutperform Votes22569.88% Underperform Votes9730.12% Scholar RockOutperform Votes16966.27% Underperform Votes8633.73% Do institutionals and insiders hold more shares of NITE or SRRK? 32.8% of Nightstar Therapeutics shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 13.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, NITE or SRRK? Nightstar Therapeutics has a beta of 2.84, indicating that its share price is 184% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Do analysts rate NITE or SRRK? Scholar Rock has a consensus price target of $42.67, indicating a potential upside of 30.04%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts plainly believe Scholar Rock is more favorable than Nightstar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nightstar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Scholar Rock 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, NITE or SRRK? Nightstar Therapeutics has higher earnings, but lower revenue than Scholar Rock. Nightstar Therapeutics is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNightstar TherapeuticsN/AN/A-$36.86M-$1.26-21.15Scholar Rock$33.19M93.77-$165.79M-$2.45-13.39 Does the media prefer NITE or SRRK? In the previous week, Scholar Rock had 14 more articles in the media than Nightstar Therapeutics. MarketBeat recorded 14 mentions for Scholar Rock and 0 mentions for Nightstar Therapeutics. Scholar Rock's average media sentiment score of 1.55 beat Nightstar Therapeutics' score of 0.00 indicating that Scholar Rock is being referred to more favorably in the news media. Company Overall Sentiment Nightstar Therapeutics Neutral Scholar Rock Very Positive SummaryScholar Rock beats Nightstar Therapeutics on 9 of the 16 factors compared between the two stocks. Get Nightstar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NITE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NITE vs. The Competition Export to ExcelMetricNightstar TherapeuticsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$893.71M$2.92B$5.44B$7.80BDividend YieldN/A1.91%5.43%4.30%P/E Ratio-21.1529.2222.1418.40Price / SalesN/A481.28389.70101.29Price / CashN/A168.6838.2034.62Price / Book4.523.036.664.18Net Income-$36.86M-$72.17M$3.21B$247.71M Nightstar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NITENightstar TherapeuticsN/A$26.65+2.4%N/A+2.4%$893.71MN/A-21.1547SRRKScholar Rock4.0148 of 5 stars$30.30+4.7%$42.67+40.8%+135.0%$2.86B$33.19M-12.84140News CoveragePositive NewsSWTXSpringWorks Therapeutics2.0732 of 5 stars$37.60+0.4%$73.20+94.7%+1.2%$2.81B$191.59M-10.78230Upcoming EarningsNews CoverageIMVTImmunovant1.9567 of 5 stars$15.38-0.3%$41.00+166.6%-47.0%$2.60BN/A-5.83120Analyst ForecastNews CoveragePositive NewsALVOAlvotech1.7818 of 5 stars$8.48-0.6%$18.00+112.4%-41.8%$2.54B$489.68M-4.564IBRXImmunityBio1.9386 of 5 stars$2.80-3.3%$12.19+336.0%-48.9%$2.41B$14.75M-3.07590Analyst ForecastTWSTTwist Bioscience3.3934 of 5 stars$39.44-1.0%$52.80+33.9%+29.1%$2.35B$330.19M-11.68990News CoverageRXRXRecursion Pharmaceuticals2.225 of 5 stars$5.58+1.2%$8.20+47.1%-26.9%$2.23B$58.49M-3.62400Gap DownVCELVericel2.5296 of 5 stars$41.50+0.7%$60.86+46.6%-12.6%$2.07B$237.22M687.78300Positive NewsDNLIDenali Therapeutics4.1562 of 5 stars$13.25-0.2%$37.57+183.6%+4.8%$1.92B$330.53M-4.79430Positive NewsTARSTarsus Pharmaceuticals2.1681 of 5 stars$48.61-0.2%$63.67+31.0%+55.2%$1.86B$182.95M-12.7150News CoveragePositive News Related Companies and Tools Related Companies SRRK Alternatives SWTX Alternatives IMVT Alternatives ALVO Alternatives IBRX Alternatives TWST Alternatives RXRX Alternatives VCEL Alternatives DNLI Alternatives TARS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NITE) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nightstar Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Nightstar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NITE Stock Free NITE Stock Alerts